Due to capacity constraints, the EUROPAC team will be undertaking a restructuring process from 1 January 2026 to 31 March 2026. During this period, EUROPAC will be closed to all new recruitment
From 1 January 2026, all EUROPAC enquiries should be directed to the centralised inboxes and not to individual email addresses
Any referrals received during the closure period will be returned to the referrer with a request to resubmit following the end of the restructuring period
Individuals who are currently in the process of registration should be advised to return their registration documentation as normal; these will continue to be processed. For participants currently under surveillance, any queries during this period should be directed to the relevant surveillance centre
In line with NICE guideline NG85, individuals with a family history of pancreatic cancer may be eligible for surveillance and should be advised to discuss this with their GP if concerned
About EUROPAC
The EUROPAC study has been ongoing for many years. It’s looking at screening for people at a high risk of developing pancreatic cancer
Since it started scans and tests to detect problems of the pancreas including cancer have improved. The main aim of the EUROPAC study is to see if these scans and tests can help diagnose pancreatic cancer earlier
Who can enter
You can join the study through a registry, helping researchers to get a better understanding of cancer risk and receiving advice and support from the EUROPAC team
You can have your details entered into 1 of the 2 registries that are part of the EUROPAC study
The 1st registry is for people who have pancreatic cancer in their family
The 2nd registry is for people who have a family history of inflammation of the pancreas (pancreatitis)
The following bullet points list the entry conditions for this study. Talk to the study team if you are unsure about any of these. They will be able to advise you
Who can take part
1. Registry:
You may be able to join the registry if at least one of the following apply:
That in your family there are 2 first degree relatives who have or had adenocarcinoma pancreatic cancer, that is parent and child, brothers or sisters
You have 3 or more relatives with adenocarcinoma pancreatic cancer
You have a medical condition that increases your risk of pancreatic cancer for example hereditary non polyposis colorectal cancer (HNPCC), familial atypical multiple mole melanoma (FAMMM) and Lynch syndrome. And 1 family member who has pancreatic cancer
Your family has a gene known to cause pancreatic cancer for example BRCA2 and at least 1 member has pancreatic cancer
You have 2 or more relatives that have inflammation of the pancreas (pancreatitis) where the cause is unknown (idiopathic)
There is at least 1 person in your family that has inflammation of the pancreas caused by a known change (mutation) in the PRSS1 gene
2. Screening:
Inclusion criteria
When you are registered the study team will assess your lifetime risk of getting pancreatic cancer
Depending on this outcome they will offer you the choice to join the secondary screening programme
Exclusion criteria
For the screening study the researchers carry out an assessment of your cancer risk
They use this and their knowledge of your family to determine if you can take part
You won’t be able to take part if the chance of you developing pancreatic cancer in the next 3 years is less than 2 out of every 100 (less than 2%)
Hospital visits
There are no hospital visits for people who join the registry only
People in the screening program attend hospital twice a year, once for clinic and bloods and once for EUS
There are 4 tests available in the screening part. The tests are:
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
For review soon
Awaiting review
Invalid notification
Coventry
Rugby & South Warwickshire
North Warwickshire
South Warwickshire
Leave feedback
You must be logged in to post a comment.